Population Pharmacokinetic Modeling and Dosing Simulations of Tobramycin in Pediatric Patients with Cystic Fibrosis-Reference-Cited by-同舟云学术

Population Pharmacokinetic Modeling and Dosing Simulations of Tobramycin in Pediatric Patients with Cystic Fibrosis

Published:2021-09-17 Issue:10 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Praet Antonin¹²,Bourguignon Laurent¹³²,Vetele Florence⁴,Breant Valentine⁴,Genestet Charlotte⁵⁶,Dumitrescu Oana⁵⁶,Doleans-Jordheim Anne²⁵⁶,Reix Philippe¹⁷,Goutelle Sylvain¹³²^ORCID

Affiliation:

1. Université Lyon, Université Lyon 1, UMR CNRS 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France

2. Université Lyon, Université Lyon 1, ISPB, Faculté de Pharmacie de Lyon, Lyon, France

3. Hospices Civils de Lyon, GH Nord, Service de Pharmacie, Lyon, France

4. Hospices Civils de Lyon, GH Est, Service de Pharmacie, Bron, France

5. Hospices Civils de Lyon, GH Nord, Institut des Agents Infectieux, Lyon, France

6. Centre International de Recherche en Infectiologie, CNRS UMR 5308, INSERM U1111, Université Claude Bernard Lyon 1, Université Lyon, Lyon, France

7. Hospices Civils de Lyon, GH Est, Centre de Ressources et de Compétences de la Mucoviscidose Pédiatrique Lyon, Bron, France

Abstract

Initial dosing and dose adjustment of intravenous tobramycin in children with cystic fibrosis (CF) is challenging. The objectives of this study were to develop nonparametric population pharmacokinetic (PK) models of tobramycin in children with CF to be used for dosage design and model-guided therapeutic drug monitoring.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00737-21

Reference48 articles.

1. Cystic Fibrosis Pulmonary Guidelines

2. European Cystic Fibrosis Society Standards of Care: Best Practice guidelines

3. Clinical Response to Aminoglycoside Therapy: Importance of the Ratio of Peak Concentration to Minimal Inhibitory Concentration

4. Optimizing Aminoglycoside Therapy for Nosocomial Pneumonia Caused by Gram-Negative Bacteria

5. Pharmacodynamics of tobramycin in patients with cystic fibrosis

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Necessity of Tobramycin trough Levels in Once Daily Iv-Treatment in Patients with Cystic Fibrosis;Klinische Pädiatrie;2024-01-29

2. Therapeutic drug monitoring-guided dosing for pediatric cystic fibrosis patients: recent advances and future outlooks;Expert Review of Clinical Pharmacology;2023-07-21

3. New Recommendations of a Height-Based Dosing Regimen of Tobramycin for Cystic Fibrosis in Adults: A Population Pharmacokinetic Analysis;Therapeutic Drug Monitoring;2023-04

4. Implementation of Model-Based Dose Adjustment of Tobramycin in Adult Patients with Cystic Fibrosis;Pharmaceutics;2022-08-22

5. Cefepime precision dosing tool: From Standard to Precise Dose Using Nonparametric Population Pharmacokinetics;Antimicrobial Agents and Chemotherapy;2021-12-13